Pemetrexed-induced Sweet Syndrome: First case report in the medical literature

Basit Öğe Kaydı
dc.contributor.authorKorkmaz, Mustafa
dc.contributor.authorEryilmaz, Melek Karakurt
dc.contributor.authorKaraagac, Mustafa
dc.contributor.authorDemirkiran, Aykut
dc.contributor.authorAraz, Murat
dc.contributor.authorArtac, Mehmet
dc.date.accessioned2024-02-23T14:27:01Z
dc.date.available2024-02-23T14:27:01Z
dc.date.issued2021
dc.departmentNEÜen_US
dc.description.abstractIntroduction Sweet Syndrome, also known as acute febrile neutrophilic dermatosis, is a rare inflammatory disease characterized by the sudden emergence of painful, edematous, and erythematous papules, plaques, or nodules on the skin, which usually fully responsive to systemic corticosteroids. Skin lesions are often accompanied by fever and leukocytosis. Here we present a case of Sweet Syndrome caused by pemetrexed in metastatic lung adenocarcinoma. Case report A 52-year-old patient with metastatic lung adenocarcinoma received multiple lines of chemotherapy. The patient presented with extensive skin lesions after performing of pemetrexed chemotherapy. He had a fever and elevations in blood levels of C-reactive protein (CRP), sedimentation, leucocytes, and neutrophils. Neutrophil predominant perivascular and interstitial dermatitis, focal micropustule formation, and severe neutrophilic dermatosis were reported in skin biopsy. Topical steroid and oral antihistamine treatment were started as initial treatment. Discussion and conclusions:Cutaneous side effects related to pemetrexed are often reported as 'skin rash,' which is a non-specific term. Therefore, the diagnosis of Sweet Syndrome must be confirmed by skin biopsy. It is essential to exclude the presence of an infection and medication history. Recovery in drug-induced Sweet Syndrome occurs after the drug that caused it was discontinued. Systemic corticosteroids are the first-line treatment for most cases.en_US
dc.identifier.doi10.1177/1078155220963178
dc.identifier.endpage1310en_US
dc.identifier.issn1078-1552
dc.identifier.issn1477-092X
dc.identifier.issue5en_US
dc.identifier.pmid33028131en_US
dc.identifier.scopus2-s2.0-85092269175en_US
dc.identifier.scopusqualityQ3en_US
dc.identifier.startpage1307en_US
dc.identifier.urihttps://doi.org/10.1177/1078155220963178
dc.identifier.urihttps://hdl.handle.net/20.500.12452/14421
dc.identifier.volume27en_US
dc.identifier.wosWOS:000578249000001en_US
dc.identifier.wosqualityQ4en_US
dc.indekslendigikaynakWeb of Scienceen_US
dc.indekslendigikaynakScopusen_US
dc.indekslendigikaynakPubMeden_US
dc.language.isoenen_US
dc.publisherSage Publications Ltden_US
dc.relation.ispartofJournal Of Oncology Pharmacy Practiceen_US
dc.relation.publicationcategoryMakale - Uluslararası Hakemli Dergi - Kurum Öğretim Elemanıen_US
dc.rightsinfo:eu-repo/semantics/closedAccessen_US
dc.subjectPemetrexeden_US
dc.subjectSweet Syndromeen_US
dc.subjectAcute Febrile Neutrophilic Dermatosisen_US
dc.subjectMetastatic Lung Adenocarcinomaen_US
dc.titlePemetrexed-induced Sweet Syndrome: First case report in the medical literatureen_US
dc.typeArticleen_US

Dosyalar

Koleksiyon

WoS İndeksli Yayınlar Koleksiyonu
PubMed İndeksli Yayın Koleksiyonu
Scopus İndeksli Yayınlar Koleksiyonu